Drug intelligence / Profile preview

INR101

Development stage: Phase 3
Lead developer: Yunhe Pharmaceutical (Tianjin) Co., Ltd
Modality: Small Molecules
Administration: Intravenous

Overview

INR101 is a diagnostic radiopharmaceutical agent developed for use in PET/CT imaging, specifically targeting prostate-specific membrane antigen (PSMA). It acts as a PSMA modulator and is designed to aid in the detection and diagnosis of PSMA-positive prostate cancer. The drug is administered intravenously and is currently being evaluated in Phase 3 clinical trials for its efficacy and safety in imaging patients with suspected or confirmed prostate cancer. The primary developer and manufacturer are Yunhe Pharmaceutical (Tianjin) Co., Ltd, with active involvement from Yunhe Pharmaceutical (Shanghai) Co., Ltd[1][2][3].

Brand names: INR101INR-101INR 101
Other names: INR-101INR101INR 101

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on INR101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INR101.

Explore the full profile